Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017

  • ID: 4333998
  • Report
  • 96 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Athersys Inc
  • Cynata Therapeutics Ltd
  • GlaxoSmithKline Plc
  • Implicit Bioscience Ltd
  • Savara Inc
  • SolAeroMed Inc
  • MORE
Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 2, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Athersys Inc
  • Cynata Therapeutics Ltd
  • GlaxoSmithKline Plc
  • Implicit Bioscience Ltd
  • Savara Inc
  • SolAeroMed Inc
  • MORE
Introduction

Acute Respiratory Distress Syndrome - Overview

Acute Respiratory Distress Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Respiratory Distress Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development

Athersys Inc

Commence Bio Inc

Cynata Therapeutics Ltd

Faron Pharmaceuticals Oy

GlaxoSmithKline Plc

Hydra Biosciences Inc

Implicit Bioscience Ltd

Navigen Inc

ProMetic Life Sciences Inc

Savara Inc

Silence Therapeutics Plc

SolAeroMed Inc

Windtree Therapeutics Inc

Acute Respiratory Distress Syndrome - Drug Profiles

Aerosurf - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-10901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2586881 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2862277 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-067047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon beta-1a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lucinactant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-5093 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05285401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plasminogen (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1229 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

simvastatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TCP-25 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Respiratory Distress Syndrome - Dormant Projects

Acute Respiratory Distress Syndrome - Discontinued Products

Acute Respiratory Distress Syndrome - Product Development Milestones

Featured News & Press Releases

May 08, 2017: Faron Pharmaceuticals: Update on INTEREST Phase III Study for Traumakine in ARDS from IDMC

Oct 31, 2016: New Patent Application Accepted by Finnish Patent Office Protect the intravenous use of interferon-beta in a novel formulation

Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial

Sep 03, 2016: Queen’s University Developing New Drug against Leading Causes of Death in the UK - Sepsis and Ards

May 25, 2016: First patient dosed in Savaras pivotal trial for PAP

Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation

Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS

Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome

Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP

Aug 09, 2015: Serendex to initiate first phase II clinical trial

Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November

May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced

May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases

May 10, 2015: Positive topline data from Serendex phase I clinical trial

Feb 27, 2015: Serendex submits phase I application

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Acute Respiratory Distress Syndrome, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H2

Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H2

Acute Respiratory Distress Syndrome - Pipeline by Cynata Therapeutics Ltd, H2

Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2

Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2

Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H2

Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, H2

Acute Respiratory Distress Syndrome - Pipeline by Navigen Inc, H2

Acute Respiratory Distress Syndrome - Pipeline by ProMetic Life Sciences Inc, H2

Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H2

Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H2

Acute Respiratory Distress Syndrome - Pipeline by SolAeroMed Inc, H2

Acute Respiratory Distress Syndrome - Pipeline by Windtree Therapeutics Inc, H2

Acute Respiratory Distress Syndrome - Dormant Projects, H2

Acute Respiratory Distress Syndrome - Dormant Projects, H2 2017 (Contd..1), H2

Acute Respiratory Distress Syndrome - Discontinued Products, H2

List of Figures

Number of Products under Development for Acute Respiratory Distress Syndrome, H2

Number of Products under Development by Companies, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Top 10 Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Athersys Inc
  • Commence Bio Inc
  • Cynata Therapeutics Ltd
  • Faron Pharmaceuticals Oy
  • GlaxoSmithKline Plc
  • Hydra Biosciences Inc
  • Implicit Bioscience Ltd
  • Navigen Inc
  • ProMetic Life Sciences Inc
  • Savara Inc
  • Silence Therapeutics Plc
  • SolAeroMed Inc
  • Windtree Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll